

Guidelines for Laboratory Verification of Performance of QIAstat-Dx[®] Respiratory SARS-CoV-2 Panel

QIAGEN GmbH, QIAGEN Strasse 1, 40724 Hilden, Germany

Introduction

This document provides a sample protocol to verify the QIAstat-Dx Respiratory SARS-CoV-2 Panel (cat. no. 691214). The protocol provides positive and negative tests for the pathogens detected by the QIAstat-Dx Respiratory SARS-CoV-2 Panel.

Each laboratory is responsible for defining their verification procedure and ensuring that they meet state and federal guidelines.

Materials and methods

The procedure described below and in Table 1 generates multiple positive and negative results for each of the sample control mixes tested. The sample protocol was developed using ZeptoMetrix[®] NATtrol[®] Respiratory Verification Panel 2 available from ZeptoMetrix Corporation (Buffalo, NY; cat. no. NATRVP2-QIA).

If testing is being performed using a QIAstat-Dx Analyzer with additional Analytical Modules, the laboratory director may choose not to perform the verification protocol on each Analytical Module. If the complete verification protocol is not performed on each Analytical Module, we advise distributing test replicates evenly among the different Analytical Modules of the system.

Table 1. Overview of sample verification method

| Sample code | |
|--|-----|
| Organism controls per sample control mix | 5 |
| Number of sample control mixes | 4 |
| Replicates per sample control mix | 4 |
| QIAstat-Dx cartridges required | 16 |
| Expected number of positive results | 92 |
| Expected number of negative results | 244 |
| Approximate days of testing | 4 |
| Number of operators | 2 |

Table 2. Materials needed for the sample verification method

| Material | Catalog number | Quantity |
|---|----------------------------|---------------|
| QIAstat-Dx Respiratory SARS-CoV-2 Panel kit | 691214 | 3 |
| QIAstat-Dx Operational Module | 9002813 | 1 |
| QIAstat-Dx Analytical Module(s) | 9002814 | 1–4 |
| NATtrol Respiratory Verification Panel 2 | ZeptoMetrix NATRVP2-QIA | 1 |
| Universal transport media (UTM)* | * | At least 5 mL |
| Sample tubes, 5 mL | VWR 89497-740 (or similar) | 4 |
| Transfer pipettes | VWR 13-711-43 (or similar) | 24 |

* Refer to the QIAstat-Dx Respiratory SARS-CoV-2 Panel instructions for use for universal transport media tested with QIAstat-Dx Respiratory SARS-CoV-2 Panel.

Performance verification materials

The materials listed in Table 2 are required to perform verification with the sample protocol.

Sample verification method

This sample verification method describes how to prepare sample control mixes by mixing together 5 different organism controls using ZeptoMetrix NATtrol Respiratory Verification Panel 2. Proposed mixing of organism controls is provided in Table 3. The method tests a total of 16 sample control mixes (4 sample control mixes tested in 4 replicates each). For each assay run, the method provides either 5 or 6 positive results and, correspondingly, 16 or 15 negative results for the 21[†] pathogens, in total, which are detected and differentiated by QIAstat-Dx Respiratory SARS-CoV-2 Panel.

Any changes to this protocol should take into account additional lab personnel and number of instruments, based on individual laboratory needs.

Mix the organism controls to create control samples at the beginning of the sample verification method. The sample control mixes can be stored at –20°C for up to 3 days. Avoid multiple freeze-thaw cycles to prevent compromising sample integrity.

[†] For verifying *Legionella Pneumophila* and Bocavirus, which are not included in ZeptoMetrix NATtrol Respiratory Verification Panel 2, please use additional individual controls from ZeptoMetrix or another vendor of your choice.

Protocol

Day 1

1. Prepare Sample Control Mix 1 and Sample Control Mix 2 (refer to Table 3).
 - a. Transfer 0.2 mL of each of the organism controls in the mix to a new 5 mL tube.
 - b. Transfer the appropriate volume of universal transport medium to the 5 mL tube.
 - c. Ensure the pooled sample is effectively mixed by vortexing prior to testing.
2. Test two replicates from Sample Control Mix 1. The duplicate samples should be tested in a single day by different operators (see Table 4).
3. Repeat step 2 for Sample Control Mix 2 to be tested on the same day.
4. Store the samples at –20°C for up to 3 days for the evaluation of day-to-day variation.

Day 2

To evaluate day-to-day variation, test the remaining volume of the sample control mixes prepared on Day 1 (Sample Control Mix 1 and Sample Control Mix 2) by repeating steps 2 and 3 above.

Day 3

Prepare Sample Control Mix 3 and Sample Control Mix 4 as described in step 1. Test Sample Control Mix 3 and Sample Control Mix 4 according to steps 2 and 3.

Note: It is important to prepare only the number of sample control mixes that will be tested within 3 days of preparation. The number of samples prepared may be increased or decreased based on the laboratory's work schedule and number of QIAstat-Dx instruments.

Day 4

To evaluate day-to-day variation, test the remaining volume of the sample control mixes prepared on Day 3 (Sample Control Mix 3 and Sample Control Mix 4) by repeating steps 2 and 3 above. Table 4 details a workflow for two operators.

Table 3. Proposed organism control mixing and expected positive/negative results

| Mix | Organism | Organism control volume (mL) | UTM volume [mL] | Final volume of mix (mL) | Expected results | Number of expected negative results |
|----------------------|-----------------------|------------------------------|-----------------|--------------------------|------------------|-------------------------------------|
| Sample Control Mix 1 | Influenza A H1N1 | 0.2 | 1.0 | 2.0 | positive | 15 |
| | Corona HKU1 | 0.2 | | | positive | |
| | PIV 2 | 0.2 | | | positive | |
| | <i>C. pneumoniae</i> | 0.2 | | | positive | |
| | SARS-CoV-2 | 0.2 | | | positive | |
| Sample Control Mix 2 | Influenza B | 0.2 | 1.0 | 2.0 | positive | 16 |
| | Corona 229E | 0.2 | | | positive | |
| | PIV 4 | 0.2 | | | positive | |
| | hMPV | 0.2 | | | positive | |
| | <i>B. pertussis</i> | 0.2 | | | positive | |
| Sample Control Mix 3 | Influenza A H1N1/2009 | 0.2 | 1.0 | 2.0 | positive | 15 |
| | Corona C43 | 0.2 | | | positive | |
| | PIV 3 | 0.2 | | | positive | |
| | Rhinovirus 1A | 0.2 | | | positive | |
| | RSVA | 0.2 | | | positive | |
| Sample Control Mix 4 | Influenza A H3N2 | 0.2 | 1.0 | 2.0 | positive | 15 |
| | Corona NL63 | 0.2 | | | positive | |
| | PIV 1 | 0.2 | | | positive | |
| | Adenovirus | 0.2 | | | positive | |
| | <i>M. pneumoniae</i> | 0.2 | | | positive | |

Table 4. Workflow for the sample verification method

| | Day 1 | Day 2 | Day 3 | Day 4 |
|------------|----------------------|----------------------|----------------------|----------------------|
| Operator 1 | Sample Control Mix 1 | Sample Control Mix 1 | Sample Control Mix 3 | Sample Control Mix 3 |
| | Sample Control Mix 2 | Sample Control Mix 2 | Sample Control Mix 4 | Sample Control Mix 4 |
| Operator 2 | Sample Control Mix 1 | Sample Control Mix 1 | Sample Control Mix 3 | Sample Control Mix 3 |
| | Sample Control Mix 2 | Sample Control Mix 2 | Sample Control Mix 4 | Sample Control Mix 4 |

For up-to-date licensing information and product-specific disclaimers, see the respective QIAGEN instructions for use or user manual. QIAGEN instructions for use and user manuals are available at www.qiagen.com or can be requested from QIAGEN Technical Services or your local distributor.

Trademarks: QIAGEN®, Sample to Insight®, QIAstat-Dx® (QIAGEN Group); NATtrol™, ZeptoMetrix® (ZeptoMetrix Corporation). Registered names, trademarks, etc. used in this document, even when not specifically marked as such, may still be protected by law. 12/2024 PROM-23510-001 QPRO-9200 © 2024 QIAGEN, all rights reserved.